Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.78 USD | +0.08% | -6.10% | -16.06% |
05-10 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
05-08 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.06% | 1.17B | |
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Mirum Pharmaceuticals Shares Fall After Disappointing Data From Phase 2B Study for Biliary Atresia